Welcome to our dedicated page for MINIMED GROUP SEC filings (Ticker: MMED), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on MINIMED GROUP's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into MINIMED GROUP's regulatory disclosures and financial reporting.
MiniMed Group, Inc. reported that officer Ali Dianaty received equity-based compensation. On March 9, 2026, Dianaty was granted 13,889 performance-based RSUs, each tied to one share of MMED common stock and vesting around March 9, 2027 based on share-price performance and a divestment-related date defined in a March 1, 2026 separation agreement. On the same date, Dianaty also received 126,263 stock options with a $18.00 exercise price, expiring in 2036, vesting 33% on each of March 9, 2028 and March 9, 2029, and 34% on March 9, 2030. All holdings reported are direct and reflect compensation grants rather than open-market purchases or sales.
MiniMed Group, Inc. reported that EVP and Chief Financial Officer Chad Spooner received new equity awards. He was granted 27,778 performance-based restricted stock units, each representing one share of common stock, vesting on March 9, 2027, if MiniMed’s share price reaches at least $32.05 as of the Divestment Date. He also received options for 84,176 shares of common stock at an exercise price of $18.00 per share, vesting 33% on March 9, 2028, 33% on March 9, 2029, and 34% on March 9, 2030, with expiration on March 9, 2036.
MiniMed Group, Inc. Chief Executive Officer Dallara Que reported awards of new equity-based compensation. On March 9, 2026, Que received 83,334 performance-based restricted stock units, each representing a contingent right to one share of MiniMed common stock. These units vest on March 9, 2027 if MiniMed’s common stock closes at or above $32.05 per share as of the defined Divestment Date.
On the same date, Que also received 252,526 employee stock options with an exercise price of $18.00 per share and expiration on March 9, 2036. These options vest in tranches of 33% on each of March 9, 2028 and March 9, 2029, and 34% on March 9, 2030, providing a long-term incentive structure tied to future service and share price performance.
MiniMed Group, Inc. completed its initial public offering of 28,000,000 shares of common stock at $20.00 per share, generating net proceeds of approximately $538 million. The company retained $309 million, resulting in approximately $350 million of cash on hand, and used the remainder to repay intercompany debt owed to Medtronic.
MiniMed was separated from Medtronic’s Diabetes business, with Medtronic now owning approximately 90.03% of outstanding shares. The company established a $500 million five-year senior secured revolving credit facility for working capital and general corporate purposes, reconstituted its board and committees, and adopted new equity, incentive, deferred compensation, and retirement plans for directors and executives.
MiniMed Group, Inc. director Brett A. Wall filed an initial Form 3 to report his status as an insider of the company. The filing does not list any reportable transactions or derivative positions, indicating that this document serves primarily as a baseline ownership and affiliation disclosure.
MiniMed Group, Inc. filed an initial ownership report for director Walter Matthew R. This Form 3 filing for ticker MMED identifies him as a director of the company. The filing does not report any specific stock transactions or holdings, serving only as a baseline disclosure of insider status.
MiniMed Group, Inc. director Mauri Laura has filed an initial insider ownership report on Form 3 for shares of MMED. The filing lists Mauri as a director and reports no insider stock transactions or derivative positions in the data provided.
MiniMed Group, Inc. director Timothy A. Wicks filed an initial ownership report on Form 3. The filing does not list any common stock or derivative transactions, serving as a baseline disclosure of his status as a director of the company.
MiniMed Group, Inc. filed an initial Form 3 for director Robert (Bob) Hopkins, formally registering him as an insider of the company. The filing shows no reported purchases, sales, gifts, exercises, or other transactions, and lists no derivative securities positions in the provided data.
MiniMed Group, Inc. director D. Keith Grossman filed an initial Form 3 insider ownership report for MMED. This filing establishes his status as a director and provides a baseline disclosure of his beneficial ownership. The report shows no insider transactions or derivative positions in this submission.